PE20150974A1 - Derivados de piridina - Google Patents
Derivados de piridinaInfo
- Publication number
- PE20150974A1 PE20150974A1 PE2015000616A PE2015000616A PE20150974A1 PE 20150974 A1 PE20150974 A1 PE 20150974A1 PE 2015000616 A PE2015000616 A PE 2015000616A PE 2015000616 A PE2015000616 A PE 2015000616A PE 20150974 A1 PE20150974 A1 PE 20150974A1
- Authority
- PE
- Peru
- Prior art keywords
- pyridin
- prodrug
- imidazole
- methyl
- carboxylic acid
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 150000003222 pyridines Chemical class 0.000 abstract 2
- YGORYMZBDPFQOM-UHFFFAOYSA-N 3-[(2,5-dimethylphenyl)methyl]-5-methyl-2-pyridin-3-ylimidazole-4-carboxylic acid Chemical compound C=1C(C)=CC=C(C)C=1CN1C(C(O)=O)=C(C)N=C1C1=CC=CN=C1 YGORYMZBDPFQOM-UHFFFAOYSA-N 0.000 abstract 1
- XZRSYAKLNGUHNP-UHFFFAOYSA-N 5-methyl-3-(naphthalen-1-ylmethyl)-2-pyridin-3-ylimidazole-4-carboxylic acid Chemical compound C=1C=CC2=CC=CC=C2C=1CN1C(C(O)=O)=C(C)N=C1C1=CC=CN=C1 XZRSYAKLNGUHNP-UHFFFAOYSA-N 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 101000821903 Homo sapiens Solute carrier family 22 member 12 Proteins 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 201000001431 Hyperuricemia Diseases 0.000 abstract 1
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 abstract 1
- 102100021495 Solute carrier family 22 member 12 Human genes 0.000 abstract 1
- 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 201000006334 interstitial nephritis Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Beans For Foods Or Fodder (AREA)
- Heat Sensitive Colour Forming Recording (AREA)
Abstract
Un derivado de piridina representado por la formula (I), un profarmaco del mismo, una sal farmaceuticamente aceptable del derivado de piridina o del profarmaco, donde A es O, S, entre otros; R1 es N o CH; uno de X1 a X5 es N y los cuatro restantes son CH; R3 es H, halogeno, entre otros; R4 es un grupo carboxilo, grupo tetrazolilo, entre otros, que es util para el tratamiento o profilaxis de enfermedades asociadas con URAT1 tales como gota, hiperuricemia, hipertension, enfermedades renales tales como nefritis intersticial, diabetes, arterioesclerosis y sindrome de Lesch-Nyhan. Los compuestos preferidos son: acido 1-(2,5-dimetilbencil)-4-metil-2-(piridin-3-il)-1H-imidazol-5-carboxilico; acido 4-metil-1-(naftalen-1-ilmetil)-2-(piridin-3-il)-1H-imidazol-5-carboxilico; entre otros
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012250661 | 2012-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20150974A1 true PE20150974A1 (es) | 2015-07-04 |
Family
ID=50731196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015000616A PE20150974A1 (es) | 2012-11-14 | 2013-11-13 | Derivados de piridina |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US9637469B2 (es) |
| EP (2) | EP2944633B1 (es) |
| JP (2) | JP5774238B2 (es) |
| KR (1) | KR20150082194A (es) |
| CN (2) | CN104797570B (es) |
| AR (1) | AR093468A1 (es) |
| AU (2) | AU2013345894B2 (es) |
| BR (1) | BR112015010977A2 (es) |
| CA (1) | CA2891408A1 (es) |
| CL (1) | CL2015001279A1 (es) |
| CY (1) | CY1120127T1 (es) |
| DK (1) | DK2944633T3 (es) |
| ES (1) | ES2662444T3 (es) |
| HR (1) | HRP20180451T1 (es) |
| HU (1) | HUE037736T2 (es) |
| IL (2) | IL238539A (es) |
| LT (1) | LT2944633T (es) |
| MA (1) | MA38078B1 (es) |
| ME (1) | ME03016B (es) |
| MX (1) | MX2015003672A (es) |
| NO (1) | NO2944633T3 (es) |
| NZ (1) | NZ708031A (es) |
| PE (1) | PE20150974A1 (es) |
| PH (1) | PH12015501037A1 (es) |
| PL (1) | PL2944633T3 (es) |
| PT (1) | PT2944633T (es) |
| RS (1) | RS57090B1 (es) |
| RU (1) | RU2640588C2 (es) |
| SA (1) | SA515360431B1 (es) |
| SG (2) | SG11201503770VA (es) |
| SI (1) | SI2944633T1 (es) |
| SM (1) | SMT201800322T1 (es) |
| TW (1) | TWI666205B (es) |
| UA (1) | UA117359C2 (es) |
| WO (1) | WO2014077285A1 (es) |
| ZA (1) | ZA201503322B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3144306B1 (en) * | 2014-05-13 | 2017-11-15 | Teijin Pharma Limited | Pyrazine derivative |
| MX2016014692A (es) * | 2014-05-13 | 2017-02-23 | Teijin Pharma Ltd | Polimorfos cristalinos novedosos de derivados de piridina y metodo para producirlos. |
| MX2018011214A (es) * | 2016-03-15 | 2019-03-28 | Bayer Cropscience Ag | Sulfonamidas sustituidas para controlar plagas animales. |
| CN107286156A (zh) * | 2016-04-05 | 2017-10-24 | 江苏新元素医药科技有限公司 | 新型urat1抑制剂及其在医药上的应用 |
| CN106008488B (zh) * | 2016-05-20 | 2018-10-30 | 广东东阳光药业有限公司 | 氰基吲哚类衍生物及其制备方法和用途 |
| ES2961901T3 (es) * | 2016-05-23 | 2024-03-14 | Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd | Tiofeno, método de fabricación del mismo y aplicación farmacéutica del mismo |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| UY37556A (es) | 2017-01-10 | 2018-07-31 | Bayer Ag | Derivados heterocíclicos como pesticidas |
| CN110312718B (zh) | 2017-01-10 | 2023-02-28 | 拜耳公司 | 作为害虫防治剂的杂环烯衍生物 |
| CN108658879A (zh) * | 2017-03-29 | 2018-10-16 | 天津药物研究院有限公司 | 一种urat1抑制剂及其制备方法和用途 |
| CN109251184B (zh) * | 2017-07-13 | 2021-06-15 | 浙江海正药业股份有限公司 | 一种2-三氟甲基苯磺酰胺类衍生物的医药用途 |
| CA3093445A1 (en) | 2018-03-08 | 2019-11-28 | Incyte Corporation | Aminopyrazine diol compounds as pi3k-.gamma. inhibitors |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| TWI820231B (zh) | 2018-10-11 | 2023-11-01 | 德商拜耳廠股份有限公司 | 用於製備經取代咪唑衍生物之方法 |
| CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
| WO2021089673A1 (de) | 2019-11-07 | 2021-05-14 | Bayer Aktiengesellschaft | Substituierte sulfonylamide zur bekämpfung tierischer schädlinge |
| JP2023532548A (ja) | 2020-07-02 | 2023-07-28 | バイエル・アクチエンゲゼルシヤフト | 有害生物防除剤としてのヘテロサイクレン誘導体 |
| CN114315729B (zh) * | 2021-12-09 | 2024-01-26 | 大连理工大学 | 1-苄基-2，4-二芳基咪唑类化合物、合成方法及其在抗肿瘤上的应用 |
| WO2025026738A1 (en) | 2023-07-31 | 2025-02-06 | Bayer Aktiengesellschaft | 6-[5-(ethylsulfonyl)-1-methyl-1h-imidazol-4-yl]-7-methyl-3-(pentafluoroethyl)-7h-imidazo[4,5-c]pyridazine derivatives as pesticides |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1599032A (en) * | 1977-03-04 | 1981-09-30 | May & Baker Ltd | Imidazole derivatives having herbicidal activity |
| JPS5671073A (en) | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | Imidazole derivative |
| US4770689A (en) | 1986-03-10 | 1988-09-13 | Janssen Pharmaceutica N.V. | Herbicidal imidazole-5-carboxylic acid derivatives |
| PL149675B1 (pl) | 1986-03-10 | 1990-03-31 | Sposób wytwarzania nowych pochodnych kwasu 1-metyl0-1h-imidaz0l0karb0ksyl0weg0-5 | |
| DD260928A5 (de) | 1986-06-06 | 1988-10-12 | Ciba-Geigy Ag,Ch | Verfahren zur herstellung neuer aralkylimidizolderivate |
| US4851424A (en) | 1986-06-06 | 1989-07-25 | Ciba-Geigy Corporation | 1-Phenyl-lower alkyl-imidazole 4- or 5-carboxamide compounds which are useful in the treatment of epilepsy |
| JPH08119936A (ja) | 1994-10-18 | 1996-05-14 | Fujisawa Pharmaceut Co Ltd | 複素環式誘導体 |
| IT1295405B1 (it) | 1997-09-30 | 1999-05-12 | Merck Sharp & Dohme Italia S P | Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di |
| AU2001275794A1 (en) | 2000-07-28 | 2002-02-13 | Sumitomo Pharmaceuticals Co. Ltd. | Pyrrole derivatives |
| JP3999128B2 (ja) | 2001-02-22 | 2007-10-31 | 帝人株式会社 | ベンゾ［ｂ］チオフェン誘導体、およびその製造方法 |
| AU2003902828A0 (en) * | 2003-06-05 | 2003-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
| CA2706858C (en) * | 2007-11-27 | 2013-12-24 | Ardea Biosciences, Inc. | Imidazole and triazole derivatives and methods of use |
| WO2009148599A1 (en) * | 2008-06-04 | 2009-12-10 | Synta Pharmaceuticals Corp. | Pyrrole compunds that modulate hsp90 activity |
| JP2012502049A (ja) * | 2008-09-04 | 2012-01-26 | アルディア バイオサイエンス，インク． | 尿酸値を調節するための化合物、組成物及びそれを使用する方法。 |
| JP2010202575A (ja) | 2009-03-03 | 2010-09-16 | Takeda Chem Ind Ltd | 複素環化合物 |
| BR112012000606A2 (pt) * | 2009-07-10 | 2016-11-22 | Brigham & Womens Hospital | análogos de etomidato que não inibem a síntese de esteróides adrenocorticais |
| CN102035579B (zh) * | 2009-09-28 | 2014-09-03 | 夏普株式会社 | 信息反馈方法和用户设备 |
| AR081930A1 (es) * | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
| JP5485811B2 (ja) * | 2010-06-23 | 2014-05-07 | 株式会社ジャパンディスプレイ | 双方向シフトレジスタ、及びこれを用いた画像表示装置 |
| SG187795A1 (en) * | 2010-08-11 | 2013-03-28 | Millennium Pharm Inc | Heteroaryls and uses thereof |
-
2013
- 2013-11-13 NO NO13854714A patent/NO2944633T3/no unknown
- 2013-11-13 HU HUE13854714A patent/HUE037736T2/hu unknown
- 2013-11-13 SI SI201330943T patent/SI2944633T1/en unknown
- 2013-11-13 LT LTEP13854714.6T patent/LT2944633T/lt unknown
- 2013-11-13 JP JP2014547007A patent/JP5774238B2/ja not_active Expired - Fee Related
- 2013-11-13 RU RU2015122698A patent/RU2640588C2/ru active
- 2013-11-13 WO PCT/JP2013/080706 patent/WO2014077285A1/ja not_active Ceased
- 2013-11-13 US US14/441,074 patent/US9637469B2/en not_active Expired - Fee Related
- 2013-11-13 AU AU2013345894A patent/AU2013345894B2/en not_active Ceased
- 2013-11-13 SM SM20180322T patent/SMT201800322T1/it unknown
- 2013-11-13 DK DK13854714.6T patent/DK2944633T3/en active
- 2013-11-13 EP EP13854714.6A patent/EP2944633B1/en active Active
- 2013-11-13 PE PE2015000616A patent/PE20150974A1/es not_active Application Discontinuation
- 2013-11-13 HR HRP20180451TT patent/HRP20180451T1/hr unknown
- 2013-11-13 EP EP18152142.8A patent/EP3339302A1/en not_active Withdrawn
- 2013-11-13 PL PL13854714T patent/PL2944633T3/pl unknown
- 2013-11-13 KR KR1020157008457A patent/KR20150082194A/ko not_active Withdrawn
- 2013-11-13 TW TW102141292A patent/TWI666205B/zh not_active IP Right Cessation
- 2013-11-13 SG SG11201503770VA patent/SG11201503770VA/en unknown
- 2013-11-13 CN CN201380059519.0A patent/CN104797570B/zh not_active Expired - Fee Related
- 2013-11-13 RS RS20180390A patent/RS57090B1/sr unknown
- 2013-11-13 ES ES13854714T patent/ES2662444T3/es active Active
- 2013-11-13 NZ NZ708031A patent/NZ708031A/en not_active IP Right Cessation
- 2013-11-13 UA UAA201505767A patent/UA117359C2/uk unknown
- 2013-11-13 CA CA2891408A patent/CA2891408A1/en not_active Abandoned
- 2013-11-13 ME MEP-2018-91A patent/ME03016B/me unknown
- 2013-11-13 AR ARP130104172A patent/AR093468A1/es unknown
- 2013-11-13 SG SG10201705852PA patent/SG10201705852PA/en unknown
- 2013-11-13 MX MX2015003672A patent/MX2015003672A/es unknown
- 2013-11-13 CN CN201710933918.5A patent/CN107721931A/zh active Pending
- 2013-11-13 BR BR112015010977A patent/BR112015010977A2/pt not_active Application Discontinuation
- 2013-11-13 PT PT138547146T patent/PT2944633T/pt unknown
- 2013-11-13 MA MA38078A patent/MA38078B1/fr unknown
-
2015
- 2015-01-16 JP JP2015007229A patent/JP6293068B2/ja not_active Expired - Fee Related
- 2015-04-30 IL IL238539A patent/IL238539A/en not_active IP Right Cessation
- 2015-05-08 PH PH12015501037A patent/PH12015501037A1/en unknown
- 2015-05-12 CL CL2015001279A patent/CL2015001279A1/es unknown
- 2015-05-13 ZA ZA2015/03322A patent/ZA201503322B/en unknown
- 2015-05-13 SA SA515360431A patent/SA515360431B1/ar unknown
- 2015-12-17 IL IL243193A patent/IL243193A0/en unknown
-
2017
- 2017-03-22 US US15/466,088 patent/US20170190694A1/en not_active Abandoned
- 2017-07-07 AU AU2017204665A patent/AU2017204665A1/en not_active Abandoned
-
2018
- 2018-04-10 CY CY20181100389T patent/CY1120127T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20150974A1 (es) | Derivados de piridina | |
| PE20170502A1 (es) | ACIDO 4-(3-FLUORO-3-(2-(5,6,7,8-TETRAHIDRO-1,8-NAFTIRIDIN-2-IL)ETIL)PIRROLIDIN-1-IL)-3-(3-(2-METOXIETOXI)FENIL)BUTANOICO COMO ANTAGONISTA DE INTEGRINA aVß6 | |
| CR20120296A (es) | Nuevos compuestos de espiropiperidina | |
| EA201492281A1 (ru) | Соединения n-арилтриазола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar) | |
| ECSP12011799A (es) | Compuestos de espiropiperidina y uso farmacéutico de los mismos | |
| EA201492285A1 (ru) | Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar) | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| GEP201706671B (en) | Heterocyclyl compounds as mek inhibitors | |
| EA201390969A1 (ru) | Модуляторы глюкагонового рецептора | |
| EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
| PE20170141A1 (es) | Procedimiento para la preparacion de (4s)-4-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-carbox-amida y su purificacion para su uso como principio activo farmaceutico | |
| PE20141822A1 (es) | Inhibidor de la quinasa reguladora de la senal de apoptosis | |
| EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
| PE20150224A1 (es) | Inhibidores del nampt | |
| PE20170946A1 (es) | 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| CU20160192A7 (es) | Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble | |
| CU24330B1 (es) | Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral) | |
| EA201492283A1 (ru) | Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar) | |
| PE20201184A1 (es) | Compuestos espirociclicos como moduladores del receptor farnesoide x | |
| BR112014032229A2 (pt) | método para produção de 4-[5-(piridin-4-il)-1h-1,2,4-triazol-3-il) piridina-2-carbonitrila, e intermediários da mesma | |
| EA201692300A1 (ru) | Производные карбоксамида | |
| PE20181274A1 (es) | Compuestos utiles para inhibir ror-gamma-t | |
| PE20142399A1 (es) | Compuestos de pirazol como inhibidores de sglt1 | |
| CL2017001720A1 (es) | Nuevos derivados de bencimidazol como agentes antihistamínicos. | |
| EA201391744A1 (ru) | Производные 2-амино-3-(имидазол-2-ил)-пиридин-4-она и их применение в качестве ингибиторов киназы рецептора vegf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |